Emergent BioSolutions V.P. to present at conference

W. James Jackson, Ph.D., the senior vice president and chief scientific officer at Emergent BioSolutions, Inc., will speak this week on a panel titled "Vaccines for the 21st Century."

The panel, to be held May 4, will take place as part of the BIO International Convention in Chicago, Illinois.

The scientific session comes as part of the Innovations in Vaccines track, which will explore new vaccine technologies and describe new vaccine candidates that are in development as well as the potential impact of the vaccines on global health.

Dr. Jackson has more than 20 years of biopharmaceutical research and development experience, including leading research efforts related to antigen identifications and characterization, pre-clinical evaluation and initial development of bacterial vaccines in the areas respiratory, enteric and sexually transmitted diseases.

Merck, Sanofi Pasteur, Vical and Syntiron are also expected to present as part of the Innovations in Vaccines track.

Emergent BioSolutions, Inc., a bipharmaceutical company, is focused on developing, manufacturing and commercializing vaccines and antibody therapies to assist the body's immune system in preventing or treating disease.

Emergent BioSolutions, Inc.'s BioThrax is the only vaccine that the U.S. Food and Drug Administration has approved for the prevention of anthrax disease. Among the company's product pipeline targets are infectious diseases, including programs focused on anthrax, tuberculosis, typhoid, flu and chlamydia.